Human Mantle Cell Lymphoma Peripheral Blood Mononuclear Cells (Newly Diagnosed/Untreated)

Description

Human Mantle Cell Lymphoma Peripheral Blood Mononuclear Cells (Newly Diagnosed/Untreated) are derived from the peripheral blood of patients with newly diagnosed mantle cell lymphoma (MCL) who have not received any treatment. Often characterized by t(11;14)(q13;q32) translocation leading to cyclin D1 overexpression.They are malignant transformed cells of B-cell non-Hodgkin’s lymphoma.High expression of CD20, CD5, cyclin D1 (CCND1), SOX11. Morphologically, these cells usually appear as lymphocytes with medium size, irregular nuclei and concentrated chromatin, and some of them can be seen as “blastoid” variants, showing invasive growth characteristics.Tumorigenic, malignant cells capable of invasive growth and dissemination. Their functional abnormalities are manifested as enhanced anti-apoptosis ability, dysregulated proliferation and immune escape.

Application

• Human Mantle Cell Lymphoma Peripheral Blood Mononuclear Cells (Newly Diagnosed/Untreated) can be used as an in vitro cell model to study the pathogenesis of mantle cell lymphoma (MCL), such as studying the proliferation disorder, apoptosis resistance and signaling pathway abnormalities (such as BCR, NF-κB and PI3K pathways) of MCL. These cells can also be used to evaluate the efficacy and resistance mechanism of targeted drugs such as BTK inhibitors (such as ibrutinib) and BCL-2 inhibitors (such as venetoclax).